The Journal of Clinical Pharmacology

Cover image for The Journal of Clinical Pharmacology

February 2006

Volume 46, Issue 2

Pages 130–243

  1. Therapeutic Review

    1. Top of page
    2. Therapeutic Review
    3. Pharmacokinetics
    4. Pharmacokinetics and Pharmacodynamics
    5. Drug Interactions
    6. Drug Metabolism
    7. Adverse Events
  2. Pharmacokinetics

    1. Top of page
    2. Therapeutic Review
    3. Pharmacokinetics
    4. Pharmacokinetics and Pharmacodynamics
    5. Drug Interactions
    6. Drug Metabolism
    7. Adverse Events
    1. Fingolimod (FTY720) in Severe Hepatic Impairment: Pharmacokinetics and Relationship to Markers of Liver Function (pages 149–156)

      Dr John M. Kovarik, Dr Robert L. Schmouder, Dr Stefan Hartmann, Dr Gilles-Jacques Riviere, Dr Franck Picard, Dr Brigitta Voss, Dr Markus Weiss, Dr Frank Wagner and Dr Hartmut H.-J. Schmidt

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283464

    2. Variability in Renal Clearance of Substrates for Renal Transporters in Chinese Subjects (pages 157–163)

      Dr Ophelia Q. P. Yin, Dr Brian Tomlinson and Dr Moses S. S. Chow

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283838

    3. Pharmacokinetics of Olanzapine After Single-Dose Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of an Orally Disintegrating Tablet in Normal Volunteers (pages 164–171)

      Dr John S. Markowitz, Dr C. Lindsay DeVane, Dr Robert J. Malcolm, Ms Holly A. Gefroh, Dr Jun-Sheng Wang, Dr Hao-Jie Zhu and Dr Jennifer L. Donovan

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283839

    4. Pharmacokinetic Profile of Rizatriptan 10-mg Tablet and 10-mg Orally Disintegrating Tablet Administered With or Without Water in Healthy Subjects: An Open-Label, Randomized, Single-Dose, 3-Period Crossover Study (pages 172–178)

      Dr Suzanne K. Swan, Dr Harry Alcorn Jr, Mr Anthony Rodgers, Dr Carolyn M. Hustad, Ms Karen E. Ramsey, Ms Susan Woll and Dr Franck Skobieranda

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005284194

  3. Pharmacokinetics and Pharmacodynamics

    1. Top of page
    2. Therapeutic Review
    3. Pharmacokinetics
    4. Pharmacokinetics and Pharmacodynamics
    5. Drug Interactions
    6. Drug Metabolism
    7. Adverse Events
    1. Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials (pages 179–192)

      Dr Domenic A. Ciraulo, Dr Robert J. Hitzemann, Dr Eugene Somoza, Dr Clifford M. Knapp, Dr John Rotrosen, Dr Ofra Sarid-Segal, Ms Ann Marie Ciraulo, Dr David J. Greenblatt and Dr C. Nora Chiang

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005284192

  4. Drug Interactions

    1. Top of page
    2. Therapeutic Review
    3. Pharmacokinetics
    4. Pharmacokinetics and Pharmacodynamics
    5. Drug Interactions
    6. Drug Metabolism
    7. Adverse Events
    1. The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male Volunteers (pages 193–200)

      Jing-He Yan, Maria R. Marino, Robert A. Smith, Dr Vanaja Kanamaluru, Edward M. O'Mara and Dennis M. Grasela

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283462

  5. Drug Metabolism

    1. Top of page
    2. Therapeutic Review
    3. Pharmacokinetics
    4. Pharmacokinetics and Pharmacodynamics
    5. Drug Interactions
    6. Drug Metabolism
    7. Adverse Events
    1. Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin (pages 201–213)

      Dr Bill Gurley, Ms Martha A. Hubbard, Dr D. Keith Williams, Dr John Thaden, Mr Yudong Tong, Dr W. Brooks Gentry, Dr Philip Breen, Dr Danielle J. Carrier and Dr Shreekar Cheboyina

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005284854

    2. Ginkgo biloba Does Not Alter Clearance of Flurbiprofen, a Cytochrome P450-2C9 Substrate (pages 214–221)

      David J. Greenblatt, Lisa L. von Moltke, Yan Luo, Elke S. Perloff, Kelly A. Horan, Allison Bruce, Robyn C. Reynolds, Jerold S. Harmatz, Bharathi Avula, Ikhlas A. Khan and Peter Goldman

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283465

    3. Effect of R667, a Novel Emphysema Agent, on the Pharmacokinetics of Midazolam in Healthy Men (pages 222–228)

      Dr Barbara J. Brennan, Dr Angus B. Brown, Dr Stanley J. Kolis, Dr Olga Rutman, Mr Calvin Gooden and Dr Brian E. Davies

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283836

  6. Adverse Events

    1. Top of page
    2. Therapeutic Review
    3. Pharmacokinetics
    4. Pharmacokinetics and Pharmacodynamics
    5. Drug Interactions
    6. Drug Metabolism
    7. Adverse Events
    1. Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities (pages 235–243)

      Dr Keith Tan, Mr Nigel Brayshaw, Dr Konrad Tomaszewski, Dr Peter Troke and Dr Nolan Wood

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270005283837

SEARCH

SEARCH BY CITATION